Healthcare services company Astrana Health reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 55.6% year on year to $965.1 million. The company expects next quarter’s revenue to be around $982.5 million, coming in 1% above analysts’ estimates. Its non-GAAP profit of $0.74 per share was 13.8% above analysts’ consensus estimates.

Is now the time to buy ASTH? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Astrana Health’s first quarter was marked by progress in platform integration and the expansion of its AI-driven care model, leading to strong revenue growth and positive market reaction. Management credited the quarter’s momentum to disciplined growth in value-based care, successful integration of the Prospect acquisition, and increasing adoption of full-risk contracts. CEO Brandon Sim noted, “Our results increasingly reflect the advantages of the platform we have built and the way we are embedding AI across our platform.” The company also saw material operating leverage, with improvements in general and administrative efficiency and early returns from new risk-bearing arrangements.

Looking ahead, Astrana Health’s guidance is anchored in continued scaling of its full-risk model, further integration of AI into operational and clinical workflows, and maintaining disciplined cost management. Management emphasized that future performance will be driven by the maturation of recently launched contracts, prudent risk progression, and ongoing investment in technology infrastructure. Sim explained, “We believe that, as regulatory changes continue to minimize risk adjustment as a source of alpha, relative performance across the industry will be increasingly driven by underlying clinical execution and cost management.” The company remains focused on executing its strategic pillars and navigating evolving regulatory frameworks.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to the integration of the Prospect acquisition, operating leverage from AI-enabled workflows, and the expansion of full-risk arrangements across key markets.

• AI platform drives efficiencies: Astrana’s proprietary AI platform is now embedded across claims, care management, and patient engagement, reducing provider payment cycle times by over 50% and improving clinical measures such as annual wellness visit completion rates.
• Prospect integration on track: The integration of the Prospect acquisition progressed ahead of schedule, with financial standardization completed and clinical workflows now aligned under the Astrana Care model. Management reported gross provider retention above 99% and expects to achieve the high end of synergy targets.
• Full-risk contract expansion: Approximately 80% of Care Partners revenue and 40% of total membership are now under full-risk arrangements, with new contracts performing in line with underwriting expectations. This transition supports more predictable financial performance and operating leverage.
• Operating leverage and cost control: G&A expenses as a percentage of revenue declined by 70 basis points year-over-year, reflecting ongoing deployment of AI-driven workflow automation and disciplined expense management.
• Favorable Medicaid and Exchange trends: While Medicaid disenrollment was slightly higher than anticipated, acuity remained favorable due to strong patient relationships. On the Exchange, attrition tracked better than expected, offsetting some headwinds in membership dynamics.

Drivers of Future Performance

Astrana Health’s outlook is shaped by the ongoing expansion of its full-risk model, continued AI adoption, and a focus on clinical and cost management amid a shifting regulatory environment.

• Full-risk model maturation: The company expects further growth in full-risk membership, which should enhance revenue visibility and operating leverage. Management believes this transition will drive margin improvement as new cohorts mature and care management capabilities scale.
• AI-enabled operating efficiencies: Ongoing investment in AI is expected to deliver additional G&A savings and incremental clinical benefits. Management noted that new agentic care management workflows are already reducing administrative overhead and are anticipated to impact medical cost trends over time.
• Regulatory and membership dynamics: Management highlighted that future results will be influenced by evolving Medicare Advantage rate frameworks, Medicaid enrollment trends, and the successful integration of new markets, particularly Texas. Conservative guidance reflects uncertainty around membership attrition and the timing of potential regulatory contributions such as the Quality Assurance Fund.

Catalysts in Upcoming Quarters

In coming quarters, the StockStory team will focus on (1) tracking the pace of full-risk membership expansion and the maturation of these contracts, (2) monitoring incremental operating leverage from AI-enabled workflows and continued integration of Prospect, and (3) assessing the impact of regulatory developments on Medicare Advantage and Medicaid enrollment dynamics. Updates on new market entries, particularly in Texas, will also be important signposts.

Astrana Health currently trades at $38.34, up from $36.08 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Stocks That Trumped Tariffs

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.